# US 2016/0250208 A1 · Treating organ-specific t cell mediated autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250208 A1
- Document ID: US20160250208A1
- Status: Published application
- Kind: A1
- Application number: 15/027,399
- Filed: 2014-10-10
- Published: 2016-09-01
- Earliest claimed: 2013-10-11
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Joonsoo Kang; Leslie Berg; Nitya Jain
- Web page: https://patentgrep.com/patent/US20160250208A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/425: Thiazoles
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The specification provides methods of treating a subject with an organ-specific T cell mediated autoimmune disease.

## Claims

### Claim 1

A method of treating a subject with an organ-specific T cell mediated autoimmune disease, the method comprising:
identifying a subject in need of treatment for an organ-specific T cell mediated autoimmune disease; and
administering to the subject a therapeutically effective amount of an interleukin-2-inducible T cell kinase (ITK) inhibitor,
thereby treating the subject with the organ-specific T cell mediated autoimmune disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ITK inhibitor is selected from the group consisting of BM S509744, ibrutinib, 10n, 2-amino -5 -(thio aryl)thiazo le , 5-aminomethylbenzimidazole, 2-amino-5-[(thiomethyparyl]thiazole, and biaryl thiophene.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method further comprises administering abatacept, secukinumab, or infliximab to the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the organ-specific T cell mediated autoimmune disease is selected from the group consisting of Type 1 diabetes, Hashimoto's thyroiditis, multiple sclerosis, non-infectious uveitis, Sjögren's syndrome, primary biliary cirrhosis, autoimmune hepatitis, and ankylosing spondylitis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method comprises administering the ITK inhibitor to the subject orally, intravenously, or by injection.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method inhibits migration of autoreactive T cells into a target tissue.

### Claim 9 (depends on 1)

The method of claim 1, wherein migration of alloreactive T cells is unaffected.

### Claim 10

An interleukin-2-inducible T cell kinase (ITK) inhibitor for use in treating an organ-specific T cell mediated autoimmune disease in a subject.

### Claim 11 (depends on 10)

The ITK inhibitor of claim 10, which is selected from the group consisting of BMS509744, ibrutinib, 10n, 2- amino -5 -(thio aryl)thiazo le, 5 -amino methylbenzimidazole, 2-amino-5-[(thiomethyparyl]thiazole, and biaryl thiophene.

### Claim 12 (depends on 10)

The ITK inhibitor of claim 10, in combination with abatacept, secukinumab, or infliximab, for use in treating an organ-specific T cell mediated autoimmune disease.

### Claim 13 (depends on 10)

The ITK inhibitor of claim 10, wherein the organ-specific T cell mediated autoimmune disease is selected from the group consisting of Type 1 diabetes, Hashimoto's thyroiditis, multiple sclerosis, non-infectious uveitis, Sjögren's syndrome, primary biliary cirrhosis, autoimmune hepatitis, and ankylosing spondylitis.

### Claim 14 (depends on 10)

The ITK inhibitor of claim 10, which is formulated to be administered to the subject orally, intravenously, or by injection.

### Claim 15 (depends on 10)

The ITK inhibitor of claim 10, wherein the subject is a mammal.

### Claim 16 (depends on 10)

The ITK inhibitor of claim 10, wherein the subject is a human.

### Claim 17 (depends on 10)

The ITK inhibitor of claim 10, which inhibits migration of autoreactive T cells into a target tissue.

### Claim 18 (depends on 10)

The ITK inhibitor of claim 10, wherein migration of alloreactive T cells is unaffected.
